Our Mission
NanoCure AI is building precision medicine systems designed to improve how complex disease is analyzed, interpreted, and addressed.
Our work spans AI-guided clinical workflows, therapeutic system design, and internal discovery programs. We are focused on building technologies that help move medicine from fragmented analysis toward more structured, scalable, and actionable decision-making.
We believe the next generation of healthcare will require platforms that connect biological data, clinical interpretation, and therapeutic development. NanoCure AI is building toward that future.
A Platform Built for Translational Medicine
NanoCure AI develops technologies across three integrated areas: clinical intelligence, therapeutic systems, and computational discovery. Each area supports the same larger goal — building more precise systems for understanding disease and advancing future treatment strategies.
Clinical Intelligence
AI-guided systems designed to support image-based review, cell-level analysis, and structured clinical interpretation workflows.
Therapeutic Systems
Platform development focused on novel system architectures intended to improve therapeutic precision and future intervention strategies.
Computational Discovery
Internal biological modeling and translational discovery programs designed to guide future development opportunities.
Our Medical & Technical Co-Founders
The NanoCure AI founding team brings experience across artificial intelligence, medical imaging, nanotechnology, precision engineering, and the study of hematologic malignancies. Collectively, our founders have contributed to more than 40 patents and 150 peer-reviewed publications, spanning FDA-cleared imaging systems, real-time AI inference pipelines, biocompatible nanomaterials, and translational research in blood-borne and solid-tumor diseases.
​
Our engineers and scientists bring together deep expertise in advanced optics, AI-driven analysis, and electromagnetic control, the essential building blocks of our intelligent therapeutic system. Collectively, they have designed and delivered high-speed microscopy platforms, closed-loop feedback architectures, and regulated medical-device technologies, embodying the intersection of innovation and clinical precision.
​
Together, we are creating a first-in-class, non-toxic therapeutic platform that redefines how the world detects and eliminates disease, at the cellular level and in real time.
Medical Advisory Board
Our Medical Advisory Board brings together leaders in oncology, biomedical engineering, and clinical research who share a single mission: to heal without harm. These advisors provide strategic and scientific guidance that bridges discovery, validation, and patient application.
Their collective experience spans FDA and EMA approvals, global oncology trials, nanotechnology innovation, and translational medicine. Each member plays a vital role in shaping NanoCure AI’s clinical pathway, ensuring our therapeutic platform advances with scientific rigor, regulatory alignment, and unwavering commitment to patient safety.
_jfif.jpg)
Dr. Ashok Srivastava
MD, Ph.D., MBA
Mahesh Chandreskharan
Ph.D., MS
The Vision Behind NanoCure AI Company
"​​I have always dreamed of creating real impact for my community, something tangible that improves lives in a lasting way. I never imagined that path would lead me to cancer therapy. I am a data-driven engineer by nature.
​
Every decision I make is rooted in research, experimentation, and evidence, not impulse. My journey toward NanoCure AI began after reading a research paper on nanoparticles and electromagnetic actuation. That single moment opened a world of possibility. When I connected those concepts with the emerging capabilities of modern microscopy and computer vision, I knew I was standing on the edge of something that could change the world.
​
For two years, I dedicated myself to designing this system, spending four to six hours each day after my full-time work in high-stress, niche networking roles at Amazon (Twitch and Kuiper). Those years were driven purely by passion and purpose.
​
NanoCure AI is more than an invention; it is my calling. I will not rest until this platform is complete. Our first therapeutic system will be the benchmark for success, and every medical device that follows will continue shaping the future of humanity, one discovery at a time."
Julius Lamar
Chief Executive Officer & Sole Inventor
Services
NanoCure AI offers innovative solutions in biotechnology, focusing on advanced research and development for healthcare advancements.
Partnerships
We engage selectively with qualified clinical, research, and strategic partners to enhance our capabilities and drive impactful results in the biotech field.
Platform
Access our active platform through structured onboarding processes, ensuring a seamless integration for our partners and collaborators.
Collaboration
We foster research collaboration and private evaluations to explore cutting-edge technologies and accelerate breakthroughs in biotechnology.
Get in Touch
NanoCure AI works with aligned partners across clinical research, workflow evaluation, platform development, and translational medicine.
We are building quietly, deliberately, and with a focus on long-term scientific and clinical value. Our platform approach allows us to support current clinical intelligence workflows while advancing broader internal programs in therapeutic systems and computational discovery.
​
-
Clinical workflow and research collaborations
-
Strategic platform partnerships
-
Translational medicine and therapeutic development relationships
-
Investor conversations with aligned long-term partners
​
​
For partnership or investor inquiries, contact:
investors@nanocureai.org
Office Location
Business Hours
Mon
Fri
9 AM to 5 PM
Strategic Partnerships
Collaboration Opportunities